1433 related articles for article (PubMed ID: 28353286)
41. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
[No Abstract] [Full Text] [Related]
42. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
43. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
Albanese F; Domenicale C; Volta M; Morari M
Biochem Soc Trans; 2022 Feb; 50(1):621-632. PubMed ID: 35225340
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
45. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
[TBL] [Abstract][Full Text] [Related]
46. The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation.
Bae EJ; Lee SJ
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165632. PubMed ID: 31812666
[TBL] [Abstract][Full Text] [Related]
47. Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson's Disease.
Lamonaca G; Volta M
Cells; 2020 Apr; 9(5):. PubMed ID: 32365906
[TBL] [Abstract][Full Text] [Related]
48. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
[TBL] [Abstract][Full Text] [Related]
49. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
50. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
[TBL] [Abstract][Full Text] [Related]
51. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
Nguyen M; Krainc D
Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
[TBL] [Abstract][Full Text] [Related]
52. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
[TBL] [Abstract][Full Text] [Related]
53. Parkinson's Disease-Related Genes and Lipid Alteration.
Fais M; Dore A; Galioto M; Galleri G; Crosio C; Iaccarino C
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299248
[TBL] [Abstract][Full Text] [Related]
54. Pathogenic mechanisms of neurodegeneration in Parkinson disease.
Mullin S; Schapira AH
Neurol Clin; 2015 Feb; 33(1):1-17. PubMed ID: 25432720
[TBL] [Abstract][Full Text] [Related]
55. [Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].
Pchelina SN; emel'ianov AK; Usenko TS
Mol Biol (Mosk); 2014; 48(1):3-14. PubMed ID: 25842821
[TBL] [Abstract][Full Text] [Related]
56. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
[TBL] [Abstract][Full Text] [Related]
57. LRRK2 at the Crossroad of Aging and Parkinson's Disease.
Hur EM; Lee BD
Genes (Basel); 2021 Mar; 12(4):. PubMed ID: 33805527
[TBL] [Abstract][Full Text] [Related]
58. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
59. NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.
Anantha J; Goulding SR; Tuboly E; O'Mahony AG; Moloney GM; Lomansey G; McCarthy CM; Collins LM; Sullivan AM; O'Keeffe GW
Mol Neurobiol; 2022 Jan; 59(1):61-76. PubMed ID: 34623600
[TBL] [Abstract][Full Text] [Related]
60. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
